ALPHAEON™ Expands Partnership with TEOXANE Laboratories

NEWPORT BEACH, Calif., April 24, 2014 /PRNewswire/ -- ALPHAEON Corporation, a leader in lifestyle healthcare and a wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today a significant expansion of its partnership with Geneva-based TEOXANE Laboratories.

Under terms of the agreement, TEOXANE will become the exclusive licensor and distributor of ALPHAEON's advanced neuromodulator, EVOSYAL, across the European Union, Central Europe, Russia and South Africa. The expanded partnership also provides TEOXANE with a right of first refusal to distribute all other ALPHAEON products and services that are brought to the European market.

ALPHAEON and TEOXANE began their partnership in August 2013, when ALPHAEON acquired an exclusive U.S. license to market the full line of TEOXANE's high-quality, market-leading products that include cosmeceuticals and hyaluronic acid-based wrinkle-fillers currently available in 90 markets outside of the U.S. Two months later, ALPHAEON further strengthened its portfolio by gaining exclusive rights to market EVOSYAL, an advanced neuromodulator, in the U.S. and several international markets.

"We are delighted to have expanded our partnership with TEOXANE," said ALPHAEON Chief Executive Officer Robert E. Grant. "TEOXANE's established direct and indirect sales channel will create market access for EVOSYAL across Europe."

EVOSYAL is an advanced Botulinum toxin Type A neuromodulator developed by Daewoong Pharmaceutical Co., Ltd., based in Seoul, South Korea. ALPHAEON acquired U.S. and certain international rights in October of 2013. EVOSYAL is both consistent in manufacturability and potency as a 900 kDa neuromodulator with high purity, which ALPHAEON believes will aid in achieving precise, predictable and long-lasting patient outcomes.

"All TEOXANE and ALPHAEON products – including EVOSYAL – are based on the best and most inventive science," said TEOXANE Founder and Chairwoman Valerie Taupin. "We are constantly looking for new ways to enhance beauty and well-being across all stages of life."

TEOXANE products contain 100 percent non-animal origin, resorbable hyaluronic acid. Hyaluronic acid dermal fillers are the most widely used aesthetic fillers worldwide. The company also has an extensive line of creams and other cosmeceuticals.

"Together with ALPHAEON we are building a tremendous track record of medical aesthetic innovation and entrepreneurship," said Taupin, who also serves as a director on the ALPHAEON board.

About ALPHAEON Corporation
ALPHAEON Corporation is a lifestyle healthcare company committed to partnering with board-certified physician specialists to bring to market and develop highly innovative technologies and services that promote patient wellness, beauty and performance. Ensuring access to leading advancements in lifestyle healthcare, the company fosters deep relationships with leading specialty physicians so patients look their best, feel their best and know they are receiving the best in lifestyle healthcare. For more information, please visit www.alphaeon.com.

About Strathspey Crown
Strathspey Crown is a growth equity firm specializing in lifestyle healthcare. Strathspey Crown uniquely partners with board-certified physician specialists to bring to market highly innovative technologies and services in the self-pay sector. The firm is founded in partnership with physician investors across three key medical specialties: plastic surgery, ophthalmology and dermatology. For more information, visit www.strathspeycrown.com.

About TEOXANE Laboratories
TEOXANE Laboratories, established in Geneva in 2003, specializes in the design and manufacture of hyaluronic acid-based wrinkle-filling products. As a result of its uncompromising commitment to innovation, quality and patient satisfaction, TEOXANE is now among the top three hyaluronic acid-based wrinkle product manufacturers in the world. With products in more than 90 countries, its alliance with U.S.-based ALPHAEON will bring its full line of products to market in the United States.

PRESS CONTACT:  

Jenna Mons, Vice President of Marketing and Communications  
Tel: 949-260-1700 
Email: [email protected]

ALPHAEON™ is a trademark of ALPHAEON
EVOSYAL™ is a trademark of Strathspey Crown LLC

SOURCE ALPHAEON Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED